Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327854 | 0.80 | KCNH2 (0.64) | KCNH2HDAC2HDAC1HDAC3 | |
| SCHEMBL1981933 | 0.80 | PTPN1 (0.59) | ERN1PTPN1HDAC2HDAC1HDAC3 | |
| SCHEMBL28745316 | 0.78 | PTPN1 (0.48) | PTPN1KCNH2HDAC2HDAC1HDAC3 | |
| SCHEMBL29744559 | 0.78 | ERN1 (0.64) | ERN1HSD17B1HSD17B2KCNH2HDAC2 | |
| SCHEMBL6068103 | 0.78 | ERN1 (0.64) | ERN1HSD17B1HSD17B2KCNH2HDAC2 | |
| SCHEMBL3953461 | 0.78 | HSD17B1 (0.71) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL172744 | 0.77 | ERN1 (0.58) | ERN1ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL17049365 | 0.77 | ERN1 (0.62) | ERN1KCNH2HDAC2HDAC1HDAC3 | |
| SCHEMBL13678958 | 0.76 | HSD17B1 (0.75) | ESR1ESR2HSD17B1 | |
| SCHEMBL7770514 | 0.75 | ERN1 (0.55) | ERN1KCNH2HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | ERN1 2623/4885ESR1 4170/4885ESR2 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.